吉利德发布瑞德西韦研究结果：有效抑制新冠病毒在人肺细胞中的复制

前瞻网2020-04-28

严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-2和未来出现的冠状病毒采取安全、广谱抗病毒对策。近日发表在biorxiv上的一篇论文报告了remdesivir(RDV)(瑞德西韦)强有力地抑制SARS-CoV-2在人类肺细胞中和原代人气道上皮细胞...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2030847402?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","is_english":false,"pubTime":"2020-04-28 17:53","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2030847402","market":"us","top_or_hot":-1,"title":"吉利德发布瑞德西韦研究结果：有效抑制新冠病毒在人肺细胞中的复制","media":"前瞻网","content":"<div>\n<p>严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-2和未来出现的冠状病毒采取安全、广谱抗病毒对策。近日发表在biorxiv上的一篇论文报告了remdesivir(RDV)(瑞德西韦)强有力地抑制SARS-CoV-2在人类肺细胞中和原代人气道上皮细胞...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202004281804167afea2d9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德发布瑞德西韦研究结果：有效抑制新冠病毒在人肺细胞中的复制</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德发布瑞德西韦研究结果：有效抑制新冠病毒在人肺细胞中的复制\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-04-28 17:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202004281804167afea2d9&s=b><strong>前瞻网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-2和未来出现的冠状病毒采取安全、广谱抗病毒对策。近日发表在biorxiv上的一篇论文报告了remdesivir(RDV)(瑞德西韦)强有力地抑制SARS-CoV-2在人类肺细胞中和原代人气道上皮细胞...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202004281804167afea2d9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202004281804167afea2d9&s=b","article_id":"2030847402","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202004281804167afea2d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2030847402","pubTimestamp":1588067588,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"Geely Releases Redschivir Research Results: Effectively Inhibits Novel Coronavirus Replication in Human Lung Cells","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)于2019年出现，成为新型大流行性病毒性疾病COVID-19的病原体。由于没有获得批准的治疗方法，本次大流行表明迫切需要针对SARS-CoV-2和未来出现的冠状病毒采取安全、广谱抗病毒对策。近日发表在biorxiv上的一篇论文报告了remdesivir(RDV)(瑞德西韦)强有力地抑制SARS-CoV-2在人类肺细胞中和原代人气道上皮细胞培养中的复制(EC50 = 0.01 μM)。由于其低代谢RDV的能力，在Vero E6细胞(EC50 = 1.65 μM)中观察到较弱的活动。为了快速评估体内疗效，研究人员设计了一个嵌合的SARS-CoV，编码SARS-CoV-2病毒的RDV(依赖RNA的RNA聚合酶)靶点。在嵌合病毒感染的小鼠中，与经载药处理的动物相比，治疗性RDV减少了肺病毒载量，改善了肺功能。研究人员表示，这些数据为RDV在体内外对SARS-CoV-2具有强大的活性提供了大量证据，为进一步的COVID-19治疗的临床试验提供了支持。该研究作者隶属于Gilead Sciences, Inc.，是公司的雇员，拥有公司的股份。其他作者没有利益冲突的报告。Gilead(吉利德公司)生产瑞德西韦，这种药被认为是治疗新冠肺炎的有希望的药物。不过，日前有消息称瑞德西韦在中国的一项临床试验中失败了，而吉利德当时对此发布声明称，预期在本月底发布针对瑞德西韦用于新型冠状病毒肺炎重症患者的开放标签研究的结果。编译/前瞻经济学人APP资讯组原文来源：https://www.biorxiv.org/content/10.1101/2020.04.27.064279v1","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2030847402"}